Fintepla Dosage

Generic name: fenfluramine 2.2mg in 1mL
Dosage form: oral solution
Drug classes: CNS stimulants, Miscellaneous anticonvulsants

Medically reviewed by Drugs.com. Last updated on Jan 9, 2025.

Assessments Prior to Initiating FINTEPLA

Prior to starting treatment with FINTEPLA, obtain an echocardiogram assessment to evaluate for valvular heart disease and pulmonary arterial hypertension.

Dosing Information

FINTEPLA is to be administered orally and may be taken with or without food.

Dravet Syndrome

The initial starting and maintenance dosage for patients with Dravet Syndrome is 0.1 mg/kg twice daily, which can be increased weekly based on efficacy and tolerability. Table 1 provides the recommended titration schedule, if needed.
Patients with Dravet Syndrome not on concomitant stiripentol who are tolerating FINTEPLA at 0.1 mg/kg twice daily and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance dosage of 0.35 mg/kg twice daily (maximum daily dosage of 26 mg).
Patients with Dravet Syndrome taking concomitant stiripentol plus clobazam who are tolerating FINTEPLA at 0.1 mg/kg twice daily and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance dosage of 0.2 mg/kg twice daily (maximum daily dosage of 17 mg).

Lennox-Gastaut Syndrome

The initial starting dosage for patients with Lennox-Gastaut syndrome is 0.1 mg/kg twice daily, which should be increased weekly based on tolerability. Table 1 provides the recommended titration schedule.
Patients with Lennox-Gastaut syndrome not on concomitant stiripentol who are tolerating FINTEPLA should be titrated to the recommended maintenance dosage of 0.35 mg/kg twice daily (maximum daily dosage of 26 mg).
Patients with Lennox-Gastaut syndrome taking concomitant stiripentol plus clobazam who are tolerating FINTEPLA should be titrated to the recommended maintenance dosage of 0.2 mg/kg twice daily (maximum daily dosage of 17 mg).

Table 1: FINTEPLA Recommended Titration Schedule*
	Without concomitant stiripentol*		With concomitant stiripentol plus clobazam
	Weight-based Dosage	Maximum Total Daily Dosage†	Weight-based Dosage	Maximum Total Daily Dosage†
* For patients not on concomitant stiripentol in whom a more rapid titration is warranted, the dose may be increased every 4 days. † For maximum dosage with concomitant use of strong CYP1A2 or CYP2D6 inhibitors, in patients with severe renal impairment, or in patients with hepatic impairment see Dosage and Administration 2.3, 2.4, 2.5. ‡ For patients with Dravet Syndrome, dosage may be increased based on clinical response to the maximum recommended dosage, as needed. § For patients with Lennox-Gastaut syndrome, dosage should be increased as tolerated to the recommended maintenance dosage (i.e., Day 14).
Initial Dosage‡	0.1 mg/kg twice daily	26 mg	0.1 mg/kg twice daily	17 mg
Day 7	0.2 mg/kg twice daily	26 mg	0.15 mg/kg twice daily	17 mg
Day 14§	0.35 mg/kg twice daily	26 mg	0.2 mg/kg twice daily	17 mg

Dosage Modifications for Patients with Concomitant Use of Strong CYP1A2 or CYP2D6 Inhibitors (DS and LGS)

For patients with concomitant use of FINTEPLA with a strong CYP1A2 or CYP2D6 inhibitor, a maximum total daily dosage of 20 mg without concomitant stiripentol and 17 mg with concomitant stiripentol plus clobazam is recommended.

Dosage Modifications for Patients with Severe Renal Impairment (DS and LGS)

For patients with severe renal impairment (estimated glomerular filtration rate (eGFR) 15 to 29 mL/min/1.73m2), a maximum total daily dosage of 20 mg without concomitant stiripentol and 17 mg with concomitant stiripentol plus clobazam is recommended.

Dosage Modifications for Patients with Mild, Moderate, and Severe Hepatic Impairment (DS and LGS)

See Table 2 for dosage adjustments and recommendations for patients with hepatic impairment.

Table 2: FINTEPLA Dosage Modifications and Recommendations for Patients with Hepatic Impairment
Hepatic Impairment Classification	Without concomitant stiripentol*	With concomitant stiripentol plus clobazam
Hepatic Impairment Classification	Maximum total daily dosage	Maximum total daily dosage
* titrate as recommended
Mild (Child-Pugh A)	20 mg	13 mg*
Moderate (Child-Pugh B)	20 mg	Use not recommended
Severe (Child-Pugh C)	17 mg	Use not recommended

Assessments During and After Administration of FINTEPLA

To evaluate for valvular heart disease and pulmonary arterial hypertension, obtain an echocardiogram assessment every 6 months during treatment with FINTEPLA, and 3 to 6 months after the final dose of FINTEPLA.

Administration Instructions

A calibrated measuring device (either a 3 mL or 6 mL oral syringe) will be provided by the pharmacy and is recommended to measure and administer the prescribed dose accurately. A household teaspoon or tablespoon is not an adequate measuring device and should not be used.

Discard any unused FINTEPLA oral solution remaining after 3 months of first opening the bottle or the "Discard After" date on the bottle, whichever is sooner.

FINTEPLA is compatible with commercially available gastric and nasogastric feeding tubes.

Discontinuation of FINTEPLA

When discontinuing FINTEPLA, the dose should be decreased gradually. As with all antiepileptic drugs, abrupt discontinuation should be avoided when possible, to minimize the risk of increased seizure frequency and status epilepticus.